[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 1852 Introduced in Senate (IS)]
<DOC>
118th CONGRESS
1st Session
S. 1852
To amend the Public Health Service Act to reauthorize a sickle cell
disease prevention and treatment demonstration program.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
June 7, 2023
Mr. Scott of South Carolina (for himself and Mr. Booker) introduced the
following bill; which was read twice and referred to the Committee on
Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To amend the Public Health Service Act to reauthorize a sickle cell
disease prevention and treatment demonstration program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Sickle Cell Disease and Other
Heritable Blood Disorders Research, Surveillance, Prevention, and
Treatment Act of 2023''.
SEC. 2. SICKLE CELL DISEASE TREATMENT PREVENTION AND TREATMENT.
(a) In General.--Section 1106(b) of the Public Health Service Act
(42 U.S.C. 300b-5(b)) is amended--
(1) in paragraph (1)(A)(iii), by striking ``prevention and
treatment of sickle cell disease'' and inserting ``treatment of
sickle cell disease and the prevention and treatment of
complications of sickle cell disease'';
(2) in paragraph (2)(D), by striking ``prevention and
treatment of sickle cell disease'' and inserting ``treatment of
sickle cell disease and the prevention and treatment of
complications of sickle cell disease'';
(3) in paragraph (3)--
(A) in subparagraph (A), by striking ``enter into a
contract with'' and inserting ``make a grant to, or
enter into a contract or cooperative agreement with,'';
and
(B) in subparagraph (B), in each of clauses (ii)
and (iii), by striking ``prevention and treatment of
sickle cell disease'' and inserting ``treatment of
sickle cell disease and the prevention and treatment of
complications of sickle cell disease''; and
(4) in paragraph (6), by striking ``$4,455,000 for each of
fiscal years 2019 through 2023'' and inserting ``$8,205,000 for
each of fiscal years 2024 through 2028''.
(b) Sense of Congress.--It is the sense of Congress that further
research should be undertaken to expand the understanding of the causes
of, and to find cures for, heritable blood disorders, including sickle
cell disease.
<all>